Proscribe acquired          by Envision Pharma Group

Brisbane-based medical communications agency Proscribe was acquired by global scientific communications and technology business Envision Pharma Group in 2014 — Envision's first acquisition in the Asia-Pacific region.

Mark Sapsford, now Partner & Co-founder of CapEQ, advised the shareholders of Proscribe on the sale. 

Logo of Proscribe, Brisbane-based medical communications agency acquired by Envision Pharma Group
Logo of Envision Pharma Group, global scientific communications business and acquirer of Proscribe

Overview of Proscribe

Founded in Brisbane, Queensland by Professor Karen Woolley and Dr Mark Woolley, Proscribe is a specialist medical writing agency serving biopharmaceutical companies, medical device manufacturers, and academic research institutions across Australia, China, and Japan.

The business built its reputation on the ethical and transparent communication of clinical and scientific data — a position grounded in published research authored by its founders on good publication practice.

By the time of the sale, Proscribe was widely regarded as one of the leading independent medical communications agencies in the Asia-Pacific region.

start your business sale journey today
Deal at a glance
Target
Proscribe
Acquirer
Envision Pharma Group (Halifax Group backed)
Completion date
2014
Deal value
Undisclosed
Deal structure
Undisclosed — 100% share sale
Sell-side M&A advisor
Mark Sapsford Now CapEQ
Sector
Medical communications & scientific writing (M74.90)
Target HQ
Brisbane, Queensland, Australia
Founded
Founded by Prof. Karen Woolley & Dr Mark Woolley
Customer base
Biopharma, medical device & academic clients across Australia, China & Japan
Post-acquisition status
Fifth brand within Envision's Scientific Solutions division (alongside Envision, Evidence, Excel, Engage). Founders retained.
Envision Pharma Group expands into Asia-Pacific with the acquisition of Brisbane-based Proscribe

Strategic acquisition by Envision Pharma Group

Envision Pharma Group is a global scientific communications and technology business serving the pharmaceutical and life sciences industry. At the time of acquisition, Envision operated across North America and Europe with backing from US private equity firm Halifax Group, which had partnered with the business since 2013. The Proscribe transaction gave Envision its first operational footprint in the Asia-Pacific region — adding a respected medical writing capability, a senior clinical and scientific team, and direct relationships with biopharma clients across Australia, China, and Japan.

How the deal came together

The market backdrop

The global medical communications market was consolidating around a small group of internationally scaled platforms backed by private equity. For founder-led agencies in the Asia-Pacific region, the strategic question was no longer whether consolidation would reach them — it was which partner would offer the right combination of value, cultural fit, and operational continuity.

Proscribe's founders recognised that the optimal exit would involve a buyer with the scale to expand the team's opportunities, not absorb them.

Finding the right acquirer

The buyer search was deliberately international. A medcomms agency of Proscribe's reputation and geography was a scarce asset, and the universe of credible acquirers spanned the UK, the United States, and continental Europe.

Mark Sapsford pre-qualified a substantial list of internationally relevant strategic and PE-backed acquirers, then narrowed the field to a shortlist of three highly desirable candidates. Meetings were structured in New York and London to allow the founders to assess each acquirer in person and on their own terms.

Running a process that protected value

The process was structured to generate genuine competitive tension between strategic buyers — without compromising the founders' ability to assess cultural alignment.

Proscribe's sale documentation was prepared to international M&A standards before the buyer universe was approached, which removed information friction and preserved leverage through the negotiation.

Three credible offers were received, allowing the founders to negotiate from a position of choice rather than scarcity.

Completing on the right terms

The shareholders selected Envision Pharma Group as the acquiring party — a UK-headquartered, PE-backed strategic buyer with the platform to scale Proscribe's regional presence and the cultural disposition to retain its leadership team.

Founders Professor Karen Woolley and Dr Mark Woolley continued to lead the business under the new ownership, and Proscribe joined Envision's Scientific Solutions division as its fifth operating brand — alongside Envision, Evidence, Excel, and Engage.

Financial terms were not disclosed.

Enhancing the Envision Pharma Group platform

The acquisition gave Envision dedicated resources spanning three continents — North America, Europe, and Asia-Pacific — and positioned the group to provide globally coordinated scientific communications to clients with multi-region clinical programmes.

For Halifax Group, Envision's PE partner, the Asia-Pacific footprint reflected the strategic importance of the region as a hub for the pharmaceutical and biotechnology industries.

Envision Pharma Group expands into Asia-Pacific with the acquisition of Brisbane-based Proscribe
Mark Sapsford, Partner and Co-founder of CapEQ, advised the shareholders of Proscribe

M&A advisory support

Mark Sapsford advised the shareholders of Proscribe on the preparation, marketing, negotiation, and completion of the sale to Envision Pharma Group.

"Karen and Mark Woolley had built a business with an international reputation and a clear set of values. The work was to find an acquirer who recognised both — and to run a process that gave the shareholders a genuine choice between credible buyers. Three offers later, they chose the right partner on the right terms." — Mark Sapsford, Partner & Co-founder, CapEQ

About Proscribe

Proscribe is a specialist medical writing agency headquartered in Brisbane, Queensland, Australia.

Founded by Professor Karen Woolley and Dr Mark Woolley, it provides scientific and medical communications services to biopharmaceutical companies, medical device firms, and academic institutions across Australia, China, and Japan.

The agency is known for its commitment to ethical publication practice and the transparent communication of clinical evidence

Client feedback

“They say, ‘don’t start a business without an exit strategy’ and we say, ‘don’t start your exit strategy without Mark Sapsford!’.

"It's a true pleasure to provide a reference for Mark.  We hope our brief story below contributes to your decision to partner with Mark.  It will be one of the best decisions of your business career. 

"In 2013, after a careful consideration of international business brokers to assist us with the sale of our company, we selected Mark Sapsford.  

"Mark was based in the UK, but the time zone difference was never a problem.  Mark was very flexible in meeting with us and always sounded enthusiastic to speak with us…even on those early morning calls!  

"Mark used his considerable experience to carefully guide us through the entire sales process.  His welcoming and reassuring nature and his expertise and experience made the process relatively stress free and, dare we say it, enjoyable!  

"Initially, he helped us prepare our company for the sale, ensuring the content and presentation of the documentation was at an appropriate international standard.

"He also provided practical advice on how to manage our day-to-day business activities, while also preparing our business for sale.

"Mark searched for and pre-qualified a large number of suitable and interested international acquirers.  We knew Mark would be an impressive ambassador for our company.  Mark then supported us and negotiated on our behalf through a series of meetings we had with our short list of acquirers in New York and London.    Following offers from 3 potential and highly desirable acquirers, Mark helped us select a final UK buyer and supported us during the completion process.  

"We were exceptionally pleased with the outcome, with our company joining a global industry-leader based in the UK.

"We would highly recommend Mark if you are looking for a person with the integrity to gain and earn your trust and with the business expertise, networks and processes to ensure a successful sale.”

Mark & Karen Woolley, co-founders

Proscribe

Frequently asked questions

On selling a medical communications agency, the medcomms M&A landscape, and what founders in the sector should consider before approaching a sale.

What acquirers value in medical communications M&A
Strategic acquirers value four things above all: the calibre and tenure of the senior medical writing team, the depth and recurring nature of biopharma client relationships, evidence of compliance with good publication practice (GPP) and ICMJE standards, and a portfolio of therapeutic area expertise that complements the acquirer's existing capability. For a sell-side M&A process, those qualities need to be articulated and evidenced in the information memorandum before the buyer universe is approached.
Global pharmaceutical clients increasingly run multi-region clinical programmes and expect a single scientific communications partner across all of them. An agency with established Asia-Pacific presence — particularly in Australia, China, and Japan — gives a North American or European platform immediate access to local regulatory knowledge, clinical investigator networks, and time-zone coverage. For PE-backed acquirers, Asia-Pacific revenue also de-risks reliance on US and European budgets.
Medcomms agencies are most commonly valued on a multiple of normalised EBITDA, with the multiple adjusted upward for recurring or retainer-based revenue, top-tier biopharma client concentration of the right kind, demonstrable therapeutic specialisms, and a defensible senior team. Indicative ranges vary materially by buyer type and process competitiveness, which is why a structured sell-side M&A process — rather than negotiating with a single inbound approach — typically protects the most value.
Private equity-backed platforms in scientific communications and medical affairs are typically pursuing a buy-and-build strategy: scale, geographic coverage, therapeutic depth, and access to senior client-facing talent. Founder-led agencies offer all four at a more attractive entry multiple than larger competitors. For founders, the implication is that a credible sell-side adviser should be running an internationally targeted process — not waiting for an opportunistic inbound approach.
Medium & longer-term founder challenges in medcomms
In medcomms, key-person risk is rarely about commercial relationships alone — it is also about scientific credibility. Founders who personally hold publication-track records or therapeutic-area authority underwrite a portion of the agency's win rate. Buyers will probe how much of that scientific credibility is institutionalised across the senior writing team and how much sits with the founder. The most addressable mitigation is a 12 to 24-month period of deliberate authority transfer before going to market.
The credible acquirer universe for an internationally reputable medcomms agency is concentrated in the UK, North America, and continental Europe — regardless of where the agency is headquartered. A UK-based sell-side M&A advisor with strategic-buyer relationships across those geographies can run a genuinely international process. Time-zone friction is a process management issue, not a structural one; what matters is that the advisor has the relationships, the rigour, and the willingness to chase the right buyers wherever they sit.
Buyers will look closely at three concentration dimensions: revenue by client, revenue by therapeutic area, and revenue by individual product launch. An agency where 40% or more of revenue depends on a single client, a single TA, or a single launch cycle will face a valuation discount unless the relationship is multi-year, multi-product, and multi-stakeholder. Founders aiming for premium multiples should diversify across at least three of those axes before approaching a sale.
Two to three years before the intended sale, not six months. The work that materially lifts the achievable multiple — institutionalising scientific authority, reducing client concentration, formalising management succession, and clarifying recurring versus project revenue — needs that runway to land in the financials before due diligence. CapEQ's Three-Year Exit Roadmap is designed for exactly this preparation window.

We'd love to hear your story

Whether you are 12 months or three years from a potential sale, an early conversation costs you nothing and will give you a clearer view of your options.

book an intro chat with mark
Book an introductory call with Mark Sapsford, Partner and Co-founder of CapEQ